BBNX
Beta Bionics Inc.

184
Loading...
Loading...
News
all
press releases
News Placeholder
Truist starts on diabetes device makers, sees glucose monitor, insulin pump growth
Investing.com -- Truist Securities launched coverage on four diabetes technology companies, saying there is a long-term growth potential for continuous glucose monitors (CGM) and insulin pumps amid rising adoption in both type 1 and type 2 diabetes patients.
investing.com·4mo ago
News Placeholder
Beta Bionics Stock Gains After Mixed Analyst Coverage; Wolfe Bullish, Goldman Neutral
Wolfe Research initiated coverage with an ‘Outperform’ rating and a $20 target, while Goldman Sachs started at ‘Neutral’ with a $16 target, citing balanced growth prospects and valuation.
Stocktwits·4mo ago
News Placeholder
Artificial Pancreas Maker Beta Bionics Just Started Trading. Should You Buy BBNX Stock After Its IPO?
This healthcare technology company is guiding for revenue growth of 150% for Q4.
barchart.com·8mo ago

Latest BBNX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.